Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis (NASDAQ: CRIS) posted updated clinical data from its frontline Acute Myeloid Leukemia triplet study (CA-4948-104) presented at the 67th ASH Annual Meeting on December 9, 2025. The study adds emavusertib (ema) to venetoclax plus azacitidine in AML patients who were in complete remission but remained MRD-positive.
As of October 12, 2025, 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD), up from 4 of 8 (50%) reported as of July 2, 2025. The company reported no change in safety profile across the updated dataset. The first two cohorts tested ema dosing for 7 or 14 days per 28-day cycle.
Curis (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib (CA-4948), an oral IRAK4 inhibitor, at the 30th Annual Society for Neuro‑Oncology (SNO) Meeting on November 19–23, 2025.
Key presentations: poster and rapid oral presentations on Nov 21–22, 2025 reporting emavusertib plus BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) by Dr. Christian Grommes, Dr. Lakshmi Nayak and Cecilia Merrigan; and an oral talk on Nov 23, 2025 by Christina von Roemeling on targeting Myddosome signaling in melanoma brain metastases. Times listed are local ET and HT for each session.
Curis (NASDAQ: CRIS) reported third-quarter 2025 results and clinical progress on Nov 6, 2025. The company posted a Q3 net loss of $7.7M ($0.49/share) vs $10.1M a year earlier and revenues of $3.2M. R&D expense fell to $6.4M in Q3. Cash and cash equivalents were $9.1M at Sept 30, 2025, with a runway into Q1 2026; ~12.7M shares outstanding. Operationally, Curis continues enrollment in PCNSL TakeAim (seeking accelerated US/EU filings), filed a Phase 2 CLL protocol (first patient late Q4/early Q1), reported AML triplet MRD data (50% MRD conversion, data cut Jul 2, 2025), and holds orphan designation in PCNSL.
Curis (NASDAQ: CRIS) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.
Participants can join by dialing (800) 836-8184 (U.S.) or (646) 357-8785 (international), via the live audio webcast linked from the company's events & presentations page, and a replay will be available at www.curis.com.
Curis (NASDAQ: CRIS) announced on October 1, 2025 that its independent Compensation Committee approved inducement stock option grants to two new employees totaling 84,750 shares (the "Q4 2025 Inducement Grants").
Each option has an exercise price equal to the closing price of Curis common stock on October 1, 2025, a 10-year term, and vests over four years: 25% at first anniversary of hire and then 6.25% every three months, subject to continued service. The awards were granted outside the company's 2010 Stock Incentive Plan as inducements to accept employment.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced upcoming presentations at two major healthcare conferences in September 2025.
CEO James Dentzer will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, at 9:45 am ET, and deliver a company presentation at the H.C. Wainwright Global Investment Conference on September 10, 2025, at 10:00 am ET. Both presentations will be available via webcast on the company's investor relations website.
Curis (NASDAQ: CRIS) reported its Q2 2025 financial results and business updates, focusing on the development of emavusertib, their oral IRAK4 inhibitor. The company reported a net loss of $8.6 million ($0.68 per share), an improvement from $11.8 million loss in Q2 2024. Revenues increased to $2.7 million, up from $2.5 million year-over-year.
Key operational highlights include continued enrollment in the TakeAim Lymphoma study for PCNSL patients, completion of enrollment in the TakeAim Leukemia Phase 1/2 study, and plans to initiate a new clinical study combining emavusertib with BTKi in CLL patients. The company's cash position stands at $10.1 million, with recent offerings extending runway into Q1 2026.
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its second quarter 2025 financial results announcement for August 5, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone or access the live audio webcast through the company's website. A replay will be available at www.curis.com.
Curis (NASDAQ: CRIS) has announced a combined $7.0 million financing through a registered direct offering and concurrent private placement. The company will issue 1,538,460 shares of common stock in a registered direct offering and unregistered pre-funded warrants for up to 1,538,461 shares in a private placement.
The transaction includes Common Warrants to purchase up to 3,076,921 shares at an exercise price of $2.15 per share. The combined purchase price is $2.275 for one share and associated Common Warrant, and $2.265 for one Pre-Funded Warrant and associated Common Warrant. The offerings are expected to close around July 3, 2025.
Proceeds will support research, development, working capital, and general corporate purposes for Curis's development of emavusertib, an oral IRAK4 inhibitor.
Curis (NASDAQ: CRIS) has announced the approval of inducement stock options for its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy. The grant, approved by the Board of Directors, allows Dr. Hamdy to purchase 200,000 shares of Curis common stock at an exercise price equal to the closing price on May 1, 2025.
The stock options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and an additional 6.25% vesting every three months thereafter, contingent on Dr. Hamdy's continued employment. The grant was made outside of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan as an inducement for Dr. Hamdy's employment.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
